

# Catarina M Quinzii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9009432/publications.pdf>

Version: 2024-02-01

59  
papers

3,274  
citations

159585

30  
h-index

168389

53  
g-index

60  
all docs

60  
docs citations

60  
times ranked

4472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutant CHCHD10 causes an extensive metabolic rewiring that precedes OXPHOS dysfunction in a murine model of mitochondrial cardiomyopathy. <i>Cell Reports</i> , 2022, 38, 110475.	6.4	11
2	Mechanisms and Therapeutic Effects of Benzoquinone Ring Analogs in Primary CoQ Deficiencies. <i>Antioxidants</i> , 2022, 11, 665.	5.1	3
3	Abnormalities of hydrogen sulfide and glutathione pathways in mitochondrial dysfunction. <i>Journal of Advanced Research</i> , 2021, 27, 79-84.	9.5	11
4	Regulatory environment for novel therapeutic development in mitochondrial diseases. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 292-300.	3.6	1
5	ETMM-04. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA MODEL SYSTEMS. <i>Neuro-Oncology Advances</i> , 2021, 3, i15-i15.	0.7	0
6	Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	25
7	Metabolic Targets of Coenzyme Q10 in Mitochondria. <i>Antioxidants</i> , 2021, 10, 520.	5.1	37
8	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. <i>Nature Communications</i> , 2021, 12, 5203.	12.8	38
9	MET Inhibition Elicits PGC1 $\alpha$ -Dependent Metabolic Reprogramming in Glioblastoma. <i>Cancer Research</i> , 2020, 80, 30-43.	0.9	35
10	Coenzyme Q10 modulates sulfide metabolism and links the mitochondrial respiratory chain to pathways associated to one carbon metabolism. <i>Human Molecular Genetics</i> , 2020, 29, 3296-3311.	2.9	16
11	Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. <i>Cells</i> , 2020, 9, 1661.	4.1	20
12	Inefficient thermogenic mitochondrial respiration due to futile proton leak in a mouse model of fragile X syndrome. <i>FASEB Journal</i> , 2020, 34, 7404-7426.	0.5	26
13	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. <i>Journal of Clinical Investigation</i> , 2020, 130, 3699-3716.	8.2	104
14	Redefining infantile-onset multisystem phenotypes of coenzyme Q10-deficiency in the next-generation sequencing era. , 2020, 4, 22-35.		6
15	TAMI-33. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii220-ii220.	1.2	0
16	Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. <i>Npj Genomic Medicine</i> , 2019, 4, 18.	3.8	29
17	A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. <i>Brain</i> , 2019, 142, 2756-2774.	7.6	35
18	Activation of $\text{LXR}^{\beta}$ inhibits tumor respiration and is synthetically lethal with $\text{Bcl-2}$ inhibition. <i>EMBO Molecular Medicine</i> , 2019, 11, e10769.	6.9	32

#	ARTICLE	IF	CITATIONS
19	Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure. <i>Thorax</i> , 2019, 74, 1099-1101.	5.6	7
20	Coenzyme Q10 Deficiency. , 2019, , 169-182.		0
21	Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice. <i>Human Molecular Genetics</i> , 2019, 28, 209-219.	2.9	9
22	Metabolic studies of a patient harbouring a novel S487L mutation in the catalytic subunit of AMPK. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1896-1903.	3.8	1
23	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3588-3597.	3.8	32
24	Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy. <i>Stem Cell Reports</i> , 2018, 11, 1185-1198.	4.8	46
25	CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3708-3722.	3.8	35
26	Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 3941-3954.	7.0	35
27	Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5392-5406.	7.0	67
28	Emerging therapies for mitochondrial diseases. <i>Essays in Biochemistry</i> , 2018, 62, 467-481.	4.7	113
29	Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. <i>Scientific Reports</i> , 2018, 8, 7373.	3.3	6
30	Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias. <i>Current Neuropharmacology</i> , 2018, 17, 21-32.	2.9	4
31	A Novel SUCLA2 Mutation Presenting as a Complex Childhood Movement Disorder. <i>Journal of Child Neurology</i> , 2017, 32, 246-250.	1.4	15
32	Coenzyme Q deficiency causes impairment of the sulfide oxidation pathway. <i>EMBO Molecular Medicine</i> , 2017, 9, 96-111.	6.9	61
33	The Role of Sulfide Oxidation Impairment in the Pathogenesis of Primary CoQ Deficiency. <i>Frontiers in Physiology</i> , 2017, 8, 525.	2.8	41
34	Coenzyme Q10 as a Peripheral Biomarker for Multiple System Atrophy. <i>JAMA Neurology</i> , 2016, 73, 917.	9.0	7
35	Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 663-672.	1.7	57
36	The clinical heterogeneity of coenzyme Q <sub>10</sub> deficiency results from genotypic differences in the <i>Coq9</i> gene. <i>EMBO Molecular Medicine</i> , 2015, 7, 670-687.	6.9	77

#	ARTICLE	IF	CITATIONS
37	CoQ10 Deficiency Is Not a Common Finding in GLUT1 Deficiency Syndrome. <i>JIMD Reports</i> , 2015, 29, 47-52.	1.5	7
38	Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway. <i>Human Molecular Genetics</i> , 2015, 24, 4516-4529.	2.9	23
39	Pathomechanisms in Coenzyme Q10-Deficient Human Fibroblasts. <i>Molecular Syndromology</i> , 2014, 5, 163-169.	0.8	23
40	Clinical Presentations of Coenzyme Q10 Deficiency Syndrome. <i>Molecular Syndromology</i> , 2014, 5, 141-146.	0.8	38
41	Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. <i>EMBO Molecular Medicine</i> , 2014, 6, 1016-1027.	6.9	79
42	Multiple System Atrophy and Amyotrophic Lateral Sclerosis in a Family With Hexanucleotide Repeat Expansions in <i>C9orf72</i> . <i>JAMA Neurology</i> , 2014, 71, 771.	9.0	66
43	Supercompetitor Status of <i>Drosophila Myc</i> Cells Requires p53 as a Fitness Sensor to Reprogram Metabolism and Promote Viability. <i>Cell Metabolism</i> , 2014, 19, 470-483.	16.2	115
44	High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ Function In Vivo. <i>Cell Metabolism</i> , 2014, 19, 539-547.	16.2	82
45	Tissue-specific oxidative stress and loss of mitochondria in CoQ10-deficient <i>Pdss2</i> mutant mice. <i>FASEB Journal</i> , 2013, 27, 612-621.	0.5	61
46	Cerebellar Ataxia and Deficiency. , 2013, 1, 1004.		3
47	CoQ10 deficiencies and MNGIE: Two treatable mitochondrial disorders. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 625-631.	2.4	83
48	Effects of Inhibiting CoQ10 Biosynthesis with 4-nitrobenzoate in Human Fibroblasts. <i>PLoS ONE</i> , 2012, 7, e30606.	2.5	40
49	Primary and secondary CoQ10 deficiencies in humans. <i>BioFactors</i> , 2011, 37, 361-365.	5.4	96
50	Coenzyme Q and mitochondrial disease. <i>Developmental Disabilities Research Reviews</i> , 2010, 16, 183-188.	2.9	157
51	Treatment of CoQ10 Deficient Fibroblasts with Ubiquinone, CoQ Analogs, and Vitamin C: Time- and Compound-Dependent Effects. <i>PLoS ONE</i> , 2010, 5, e11897.	2.5	92
52	Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. <i>FASEB Journal</i> , 2010, 24, 3733-3743.	0.5	142
53	ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 Deficiency. <i>American Journal of Human Genetics</i> , 2008, 82, 661-672.	6.2	290
54	X-Linked Dominant Scapulooperoneal Myopathy Is Due to a Mutation in the Gene Encoding Four-and-a-Half-LIM Protein 1. <i>American Journal of Human Genetics</i> , 2008, 82, 208-213.	6.2	108

#	ARTICLE	IF	CITATIONS
55	Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ <sub>10</sub> deficiency. FASEB Journal, 2008, 22, 1874-1885.	0.5	150
56	CoQ10 deficiency diseases in adults. Mitochondrion, 2007, 7, S122-S126.	3.4	55
57	Human Coenzyme Q10 Deficiency. Neurochemical Research, 2007, 32, 723-727.	3.3	163
58	Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) Mutations. American Journal of Human Genetics, 2006, 79, 1125-1129.	6.2	359
59	Inefficient Thermogenic Mitochondrial Respiration Due to Futile Proton Leak in a Mouse Model of Fragile X Syndrome. SSRN Electronic Journal, 0, , .	0.4	0